12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cornerstone Therapeutics, EKR deal

Cornerstone will acquire EKR for $125 million in cash plus up to $25 million in milestones over the next three years. Cornerstone said the deal expands its product offerings and commercial infrastructure in the hospital market. EKR had $58 million in net revenue last year,...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >